627. Aggressive Lymphomas: Clinical and Epidemiological: Clinical Management of Aggressive B cell NHL
Jakoba J Eertink, Gerben J.C Zwezerijnen, Sanne E Wiegers, et al.
According to the authors, radiomics features can increase the efficiency of clinical trials by only selecting poor prognosis patients. See more info in the abstract.
Matthew R Wilson, Toby A. Eyre, Amy A Kirkwood, et al.
In this extensive analysis of 1L R-CHOP patients, no evidence was found that EOT administration increased the risk of CNS relapse compared to i-HDMTX. See more info in the abstract.
Rahul Lakhotia, Kieron Dunleavy, Jeremy S. Abramson, et al.
Excellent 5-year TTP (95%) and EFS (94%) were found in the multicenter NCI 9177 study in patients with Burkitt lymphoma and low- or medium-risk BL-IPI scores. Age is not prognostic with DA-EPOCH-R. In contrast, CNS /BM /PB involvement is prognostic in the BL-IPI groups.
Joachim Baech, Marianne Tang Severinsen, Andreas Kiesbye Øvlisen, et al.
Beyond the first year, patients treated with steroid-containing immunochemotherapy did not show a higher risk of DM than comparable comparator products. See more info in the abstract.
Adam Zayac, Daniel J Landsburg, Mitchell Hughes, et al.
See more info in the abstract
Paw Jensen, Lasse H. Jakobsen, Martin Bøgstede, et al.
For primary prophylaxis against glucocorticoid-induced osteoporosis in all lymphoma patient subgroups, alendronate has been shown to be clinically important, safe, and effective, with the greatest effect size in women.